Prescribing overview
Ultram is a human immediate-release tramadol product and US Schedule IV controlled substance. Animal effectiveness cannot be inferred from human approval.
Key prescribing checks
- The human label warns about respiratory depression, dependence, seizures and serotonin syndrome. Veterinary screening should identify relevant interactions and patient risks.
- Review other opioids, sedatives and serotonergic drugs, including behavioral medications. Concurrent products can change both safety and clinical response.
- Human dosing instructions must not be used as veterinary instructions. Ingredient lookup does not establish that tramadol is an adequate standalone analgesic for a particular patient.
- Controlled-substance storage and dispensing requirements apply; accidental ingestion is a serious exposure.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Veterinary patients: not established by reviewed label
Extra-label veterinary use; reviewed product is human-labeledVeterinarian-selected analgesia
Animal species, pain type and formulation require independent clinical assessment.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Tramadol and its active M1 metabolite have opioid activity; tramadol also inhibits serotonin/norepinephrine reuptake.
Absorption, distribution, metabolism and elimination
No species-specific veterinary exposure or M1 formation is verified from this human label; human metabolism cannot predict an animal regimen.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Ultram
Oral tablet; Human product
Contraindications · when not to use
- Significant respiratory depression; acute/severe asthma without monitoring/resuscitation; gastrointestinal obstruction including ileus; tramadol/component/opioid hypersensitivity; MAOI use or use within fourteen days. Human restrictions also include children under twelve and post-tonsil/adenoid surgery under eighteen.
Precautions & monitoring
- Respiratory depression, dependence, seizures and serotonin syndrome are serious risks.
Human labeling; this does not establish veterinary approval or animal-specific eligibility.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Human warnings include respiratory depression, dependence, seizures and serotonin syndrome. Sedative combinations increase danger.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
A veterinary dose is not verified. Immediate-release, extended-release and combination tablets must not be substituted by ingredient name alone.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Ultram
Oral tablet; Human product
- Sedatives/CNS depressants increase respiratory risk; serotonergic and CYP2D6/CYP3A4-modifying drugs require review.
Monitoring
Assess pain relief, alertness, respiratory status and serotonergic/CNS-depressant interactions with the veterinarian.
Client counseling
Seek urgent care for difficult breathing, marked unresponsiveness, seizures or suspected overdose. Do not abruptly change sustained treatment without prescriber advice.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Store securely to prevent human or animal accidental ingestion; follow controlled-drug dispensing/disposal requirements and package conditions.
Brands, formulations & ingredient identity
Active ingredients
Tramadol
Other searchable names: tramadol hydrochloride
Ultram identifies tramadol hydrochloride tablets. A human brand name does not establish animal approval or equivalent effectiveness across species.
Extended-release and combination products are different formulations. Check the full product name and ingredients rather than matching tramadol alone.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Ultram
- Formulation
- Oral tablet
- Label / product scope
- Human product
Human tramadol hydrochloride brand; U.S. Schedule IV.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →